Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. Annual Report: A Deep Dive for Investors

This report offers retail investors a clear look into Cardio Diagnostics Holdings, Inc.'s performance for the fiscal year ended December 31, 2024. We explore the company's operations, financial health, and future prospects.

---

Business Overview

Cardio Diagnostics Holdings, Inc. (ticker: CDIO), listed on The Nasdaq Stock Market, is a precision cardiovascular medicine company. It develops and commercializes advanced diagnostic tests, leveraging cutting-edge genomic technologies to improve heart disease management.

Its flagship products, Epi+Gen CHD™ and PrecisionCHD™, are specialized epigenetic and genetic tests. These tests assess an individual's risk for coronary heart disease (CHD):

• Epi+Gen CHD™ identifies current risk by analyzing DNA methylation patterns and genetic markers.
• PrecisionCHD™ focuses on genetic predisposition.

Together, these tests aim to provide earlier, more personalized risk assessments than traditional methods, enabling proactive intervention in the rapidly evolving field of personalized medicine.

---

Financial Performance

For the fiscal year ended December 31, 2024, Cardio Diagnostics reported revenue of $1.5 million. This marks an 87.5% increase from $0.8 million in the prior year, reflecting initial commercialization success and growing adoption of its tests.

However, as a growth-stage company heavily investing in its future, Cardio Diagnostics reported a net loss of $(25.0) million, or $(5.00) per diluted share (adjusted for the subsequent reverse stock split). This loss primarily stems from substantial investments in:

• Research and development (R&D)
• Sales and marketing to expand market presence
• General and administrative expenses associated with being a public company

---

Key Risk Factors for Investors

Investors should be aware of several critical risks:

• Nasdaq Listing Compliance: Despite a reverse stock split, the company faces an ongoing risk of losing its Nasdaq listing, which could severely impact stock liquidity and investor confidence.
• Regulatory Landscape for Laboratory-Developed Tests (LDTs): Potential changes in regulations governing LDTs pose a significant risk. Increased scrutiny or new requirements from bodies like the FDA could raise costs, delay market access, and impact the company's ability to develop, market, and sell its diagnostic tests.
• Funding and Liquidity: While the "at-the-market" (ATM) offering provides capital, the company's ability to secure sufficient future financing on acceptable terms remains crucial for sustaining operations and funding R&D.
• Limited Operating History: As a relatively young company, Cardio Diagnostics has a limited track record, making it challenging to predict future performance and assess long-term viability.
• Commercialization & Market Adoption: Success depends on widespread adoption of Epi+Gen CHD™ and PrecisionCHD™. This requires securing favorable reimbursement policies, building strong sales channels, and demonstrating clinical utility and cost-effectiveness to healthcare providers and payers.
• Competition: The diagnostic market is highly competitive, with established players and emerging technologies. Cardio Diagnostics must differentiate its offerings to secure market share.
• Intellectual Property: The company's success relies on its ability to protect its proprietary technology and intellectual property, and to operate without infringing on the intellectual property rights of others.
• Reliance on Key Personnel: The loss of key management or scientific personnel could significantly impact the company's operations and strategic initiatives.

---

Management Discussion & Analysis (MD&A) Highlights

Management emphasizes a strategic focus on commercialization and product development. The significant revenue growth demonstrates early market penetration, while the substantial net loss underscores the company's investment phase, prioritizing long-term growth over immediate profitability.

Key operational challenges include navigating the complex regulatory environment for LDTs and securing adequate funding for ongoing R&D and sales and marketing expansion. Management executed a 1-for-30 reverse stock split to maintain Nasdaq listing compliance, addressing capital market requirements. The active use of an "at-the-market" (ATM) equity offering provides flexible capital raising, though it balances funding needs with potential shareholder dilution. Management stresses the importance of generating further clinical evidence and expanding commercial reach to drive future adoption and achieve sustainable growth.

---

Financial Health Snapshot

• Cash Position: As of December 31, 2024, Cardio Diagnostics held $8.0 million in cash and cash equivalents.
• Liquidity & Capital Raising: To support ongoing operations and growth, the company used an "at-the-market" (ATM) equity offering. Under this agreement, initiated in January 2024 and updated in February 2025, it sold approximately $10.0 million worth of new shares during 2024 and early 2025. This strategy offers flexible access to capital but results in dilution for existing shareholders, meaning their ownership percentage decreases as more shares are issued. The company pays a 2.5% commission on these sales.
• Debt: Equity offerings, including the ATM facility, have been the company's primary funding source. As of December 31, 2024, the company reported no significant long-term debt that would materially affect its financial leverage or liquidity.
• Market Capitalization: As of June 30, 2025, the market value of shares held by non-insiders was approximately $5.8 million. This classifies Cardio Diagnostics as a micro-cap company, a size that often implies higher volatility and risk compared to larger, more established firms.

---

Future Outlook

Cardio Diagnostics' core strategy focuses on aggressively developing and commercializing its cardiovascular diagnostic tests, Epi+Gen CHD™ and PrecisionCHD™. This includes:

• Expanding Market Reach: Boosting sales and marketing efforts to drive adoption among healthcare providers and secure broader payer coverage.
• Clinical Evidence Generation: Investing in studies to further validate the clinical utility and benefits of its tests, which is crucial for reimbursement and physician acceptance.
• Product Pipeline: Continued R&D investment will enhance existing tests and explore new diagnostic solutions or applications within cardiovascular health.
• Capital Management: Proactively managing capital through mechanisms like the ATM offering to ensure sufficient funding for operations and growth, while also exploring other financing options.

The company's future success depends on its ability to navigate regulatory challenges, secure adequate funding, and achieve significant market penetration for its innovative diagnostic solutions. While revenue growth is encouraging, the substantial net loss and ongoing capital needs highlight the inherent risks and long-term investment required in the precision medicine space. The company does not provide specific financial guidance for the upcoming fiscal year.

---

Competitive Position

The market for cardiovascular diagnostics is highly competitive and rapidly evolving. Cardio Diagnostics competes with various entities, including:

• Established diagnostic companies: Large, diversified companies offering broad test portfolios, some addressing cardiovascular risk factors.
• Academic research institutions and university spin-offs: These entities often develop novel diagnostic technologies and may partner with or license to commercial companies.
• Other biotechnology and precision medicine companies: A growing number of companies develop genetic, epigenetic, or other biomarker-based tests for cardiovascular disease risk assessment and management.

Cardio Diagnostics aims to differentiate itself through its proprietary epigenetic and genetic testing approach, specifically with Epi+Gen CHD™ and PrecisionCHD™. These tests offer a unique combination of current risk assessment (epigenetics) and genetic predisposition. The company believes its tests provide a more comprehensive and personalized risk assessment than traditional methods or single-marker tests, offering a competitive advantage for earlier and more targeted interventions. However, market acceptance, reimbursement, and the ability to demonstrate superior clinical utility against existing and emerging solutions remain critical for securing and maintaining a strong competitive position.